Response to: Commentary on “Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study”
AI Summary
Full text unavailable; unable to extract specific key points from the response as cited.
Please provide the article text or a link to access it for an accurate three-point summary.
Without the source text, any summary would be speculative; I will summarise once provided.
Int J Bipolar Disord. 2026 Jun 6. doi: 10.1186/s40345-026-00428-8. Online ahead of print.ABSTRACTBACKGROUND: Patients with major depressive disorder (MDD) who exhibit high bipolarity are at...
J Gambl Stud. 2026 Jun 6. doi: 10.1007/s10899-026-10522-2. Online ahead of print.ABSTRACTGambling-related harm extends beyond the individual who gambles and affects others in their social...
Dermatol Ther (Heidelb). 2026 Jun 6. doi: 10.1007/s13555-026-01808-9. Online ahead of print.ABSTRACTINTRODUCTION: In June 2023, the US Food and Drug Administration (FDA) approved ritlecitinib (50...
Qual Life Res. 2026 Jun 6;35(7):168. doi: 10.1007/s11136-026-04194-z.ABSTRACTBACKGROUND: Concerns about measurement validation are often expressed as imperatives to use a "valid measure". However, validity is...
Qual Life Res. 2026 Jun 6;35(7):169. doi: 10.1007/s11136-026-04269-x.ABSTRACTHealth-related measures, such as Patient-Reported Outcome Measures (PROMs), are widely used in clinical practice, research, service evaluation, and...
